中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
z1期
83-85
,共3页
于湄%刘雪芹%杨志芬%张雪玲%李霞%张君娜
于湄%劉雪芹%楊誌芬%張雪玲%李霞%張君娜
우미%류설근%양지분%장설령%리하%장군나
热休克蛋白90%妊娠期高血压疾病%胎盘组织
熱休剋蛋白90%妊娠期高血壓疾病%胎盤組織
열휴극단백90%임신기고혈압질병%태반조직
Heat shock protein-90%Hypertensive disorders complicating pregnancy%Placenta
目的 通过检测热休克蛋白90(HSP90)基因在妊娠期高血压疾病(HDCP)患者胎盘组织中的表达,了解其在妊娠期高血压疾病病理生理机制中的作用.方法 用半定量RT-PCR和Western blot技术检测HSP90基因和蛋白在正常妊娠组、HDCP组、轻度子痫前期组、重度子痫前期组胎盘组织中的表达.结果 HSP90在HDCP组、轻度子痫前期组、重度子痫前期组胎盘中的蛋白和基因表达明显强于正常对照组,且呈逐渐加强的趋势,差异有统计学意义(P<0.01).结论 HSP90的升高可能与HDCP的发生和发展有非常密切的关系,监测胎盘组织中HSP90浓度为以HSP90为靶点治疗HDCP奠定初步的理论基础.
目的 通過檢測熱休剋蛋白90(HSP90)基因在妊娠期高血壓疾病(HDCP)患者胎盤組織中的錶達,瞭解其在妊娠期高血壓疾病病理生理機製中的作用.方法 用半定量RT-PCR和Western blot技術檢測HSP90基因和蛋白在正常妊娠組、HDCP組、輕度子癇前期組、重度子癇前期組胎盤組織中的錶達.結果 HSP90在HDCP組、輕度子癇前期組、重度子癇前期組胎盤中的蛋白和基因錶達明顯彊于正常對照組,且呈逐漸加彊的趨勢,差異有統計學意義(P<0.01).結論 HSP90的升高可能與HDCP的髮生和髮展有非常密切的關繫,鑑測胎盤組織中HSP90濃度為以HSP90為靶點治療HDCP奠定初步的理論基礎.
목적 통과검측열휴극단백90(HSP90)기인재임신기고혈압질병(HDCP)환자태반조직중적표체,료해기재임신기고혈압질병병리생리궤제중적작용.방법 용반정량RT-PCR화Western blot기술검측HSP90기인화단백재정상임신조、HDCP조、경도자간전기조、중도자간전기조태반조직중적표체.결과 HSP90재HDCP조、경도자간전기조、중도자간전기조태반중적단백화기인표체명현강우정상대조조,차정축점가강적추세,차이유통계학의의(P<0.01).결론 HSP90적승고가능여HDCP적발생화발전유비상밀절적관계,감측태반조직중HSP90농도위이HSP90위파점치료HDCP전정초보적이론기출.
Objective To detect heat shock protein 90 (HSP90) expression in the placenta in pregnancy induced hypertension in order to understand its role in the pathophysiology of hypertensive disorders comphcating pregnancy (HDCP).Methods The gene and protein expression of HSP90 in the placenta of normal pregnant women,gestational hypertension patients,mild preeclampsia patients,severe preeclampsia patients,by RT-PCR and Western blotting.Results The gene and protein expression of HSP90 in placenta of gestational hypertension group,mild preeclampsia group,severe preeclampsia group were significantly higher than that of normal pregnant group (P < 0.01),and it showed the increased progressively with the increasing of disease stage.Conclusion HSP90 may be involved in the onset and development of HDCP.Monitoring HSP90 concentration in the placenta which is the initial theoretical basis for the target as HSP90 for the treatment of HDCP.